Frontlight ResearchEarly access
Taking people in South KoreaPhase 3
Tests CKD-202A, a sacubitril and valsartan combination, for high blood pressure
Tests CKD-202A against valsartan in adults with essential hypertension, high blood pressure.
Key facts
- Who runs it
- Chong Kun Dang Pharmaceutical
- Where
- Wŏnju, South KoreaSee the site
- Trial code
- Registry title
- Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 324 people, planned
- Started
- 14 Oct 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sacubitril∙Valsartan(dose maintenance)
- Sacubitril∙Valsartan(dose increasing)
- Valsartan
- Record updated
- 11 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with essential hypertension (high blood pressure with no other known cause) to test CKD-202A (Sacubitril∙Valsartan).
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Essential hypertension. The record gives no stage or severity.
- Earlier treatment
- Cannot have used other clinical trial drugs within 4 weeks before the screening visit.
Main reasons for not taking part
- History of, or suspected, secondary hypertension
- Orthostatic hypotension
- Type 1 diabetes or poorly controlled diabetes
- Drug or alcohol abuse within 24 weeks before screening
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participants who are 19 years old or older
- Participants who have voluntarily decided to participate in this clinical trial and signed ICF
Who cannot take part
- Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period
- Participants who treated other clinical trial drugs within 4 weeks of screening visit
- Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug
- Participants with a history of secondary hypertension or suspected secondary hypertension
- Participants with type 1 diabetes or poorly controlled diabetes
- Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening
- Participants with a orthostatic hypotension
- Participants who are unable to participate in this clinical trial at the discretion of the investigator
Where in South Korea
- Wonju Severance Christian HospitalWŏnju, South KoreaContact: Byungsu Yoo, PITaking people
About the trial
What the trial wants to find out
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
The 3 groups in the trial
- Test Group1Treatment being tested
Treatment: Sacubitril∙Valsartan(dose maintenance)
- Test Group2Treatment being tested
Treatment: Sacubitril∙Valsartan(dose increasing)
- CONTROLExisting treatment, for comparison
Treatment: Valsartan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Active-controlled, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
- Plain-language title
- Tests CKD-202A, a sacubitril and valsartan combination, for high blood pressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 December 2025